Choi Hok-Kwok, Law Wai-Lun, Ho Judy-Wai-Chu, Chu Kin-Wah
Department of Surgery, University of Hong Kong Medical Centre, Queen Mary Hospital, Hong Kong, China.
World J Gastroenterol. 2005 Jun 28;11(24):3742-5. doi: 10.3748/wjg.v11.i24.3742.
Gastrografin is a hyperosmolar water-soluble contrast medium. Besides its predictive value for the need for operative treatment, a potential therapeutic role of this agent in adhesive small bowel obstruction has been suggested. This study aimed at evaluating the effectiveness of gastrografin in adhesive small bowel obstruction when conservative treatment failed.
Patients with adhesive small bowel obstruction were given trial conservative treatment unless there was fear of bowel strangulation. Those responded in the initial 48 h had conservative treatment continued. Patients who showed no improvement in the initial 48 h were given 100 mL of gastrografin through nasogastric tube followed by serial abdominal radiographs. Patients with the contrast appeared in large bowel within 24 h were regarded as having partial obstruction and conservative treatment was continued. Patients in which the contrast failed to reach large bowel within 24 h were considered to have complete obstruction and laparotomy was performed.
Two hundred and twelve patients with 245 episodes of adhesive obstruction were included. Fifteen patients were operated on soon after admission due to fear of strangulation. One hundred and eighty-six episodes of obstruction showed improvement in the initial 48 h and conservative treatment was continued. Two patients had subsequent operations because of persistent obstruction. Forty-four episodes of obstruction showed no improvement within 48 h and gastrografin was administered. Seven patients underwent complete obstruction surgery. Partial obstruction was demonstrated in 37 other cases, obstruction resolved subsequently in all of them except one patient who required laparotomy because of persistent obstruction. The overall operative rate in this study was 10%. There was no complication that could be attributed to the use of gastrografin.
The use of gastrografin in adhesive small bowel obstruction after unsuccessful conservative treatment is safe and reduces the need for surgical intervention.
泛影葡胺是一种高渗性水溶性造影剂。除了对手术治疗需求的预测价值外,该药物在粘连性小肠梗阻中还具有潜在的治疗作用。本研究旨在评估保守治疗失败后泛影葡胺在粘连性小肠梗阻中的有效性。
粘连性小肠梗阻患者除非存在肠绞窄风险,均给予试验性保守治疗。在最初48小时内有反应的患者继续进行保守治疗。在最初48小时内无改善的患者通过鼻胃管给予100毫升泛影葡胺,随后进行系列腹部X线检查。造影剂在24小时内进入大肠的患者被视为部分梗阻,继续进行保守治疗。造影剂在24小时内未到达大肠的患者被认为是完全梗阻,需进行剖腹手术。
纳入212例患者,共发生245次粘连性梗阻发作。15例患者因担心绞窄在入院后不久接受了手术。186次梗阻发作在最初48小时内有所改善,继续进行保守治疗。2例患者因持续性梗阻随后接受了手术。44次梗阻发作在48小时内无改善,给予泛影葡胺治疗。7例患者接受了完全梗阻手术。37例其他病例显示为部分梗阻,除1例因持续性梗阻需剖腹手术外,其余患者梗阻均随后缓解。本研究的总体手术率为10%。没有可归因于使用泛影葡胺的并发症。
保守治疗失败后,在粘连性小肠梗阻中使用泛影葡胺是安全的,可减少手术干预的需求。